Pok, Say Lee and Shabaruddin, Fatiha Hana and Dahlui, Maznah and Sockalingam, Sargunan and Mohamed Said, Mohd Shahrir and Rosman, Azmillah and Lau, Ing Soo and Isa, Liza Mohd and Hussein, Heselynn and Ng, Chin Teck and Mahadeva, Sanjiv (2018) Clinical and economic implications of upper gastrointestinal adverse events in Asian rheumatological patients on long-term non-steroidal anti-inflammatory drugs. International Journal of Rheumatic Diseases, 21 (5). pp. 943-951. ISSN 1756-1841, DOI https://doi.org/10.1111/1756-185X.13256.
Full text not available from this repository.Abstract
Aim: To determine the incidence and direct costs of NSAID-induced upper GI adverse events in Malaysian rheumatology patients. Methods: A retrospective, multi-centre, cohort study of rheumatology patients on long-term NSAIDs was conducted. Clinical data of patients treated between 2010 and 2013 were collected for a 24-month follow-up period. The costs of managing upper GI adverse events were based on patient level resource use data. Results: Six hundred and thirty-four patients met the inclusion criteria: mean age 53.4 years, 89.9% female, diagnosis of rheumatoid arthritis (RA; 59.3%), osteoarthritis (OA; 10.3%) and both RA and OA (30.3%). Three hundred and seventy-one (58.5%) patients were prescribed non-selective NSAIDs and 263 (41.5%) had cyclo-oxygenase-2 inhibitors. Eighty-four upper GI adverse events occurred, translating into a risk of 13.2% and an incidence rate of 66.2 per 1000 person-years. GI adverse events comprised: dyspepsia n = 78 (12.3%), peptic ulcer disease (PUD) n = 5 (0.79%) and upper GI bleeding (UGIB) n = 1 (0.16%). The total direct healthcare cost of managing adverse events was Malaysian Ringgit (MR) 37 352 (US dollars [USD] 11 419) with a mean cost of MR 446.81 ± 534.56 (USD 136.60 ± 163.42) per patient, consisting mainly of GI pharmacotherapy (33.8%), oesophagoduodenoscopies (23.1%) and outpatient clinic visits (18.2%). Mean cost per patient by GI events were: dyspepsia, MR 408.98 ± 513.29 (USD125.03 ± 156.92); PUD, MR 805.93 ± 578.80 (USD 246.39 ± 176.95); UGIB, MR 1601.94 (USD 489.74, n = 1). Conclusion: The economic burden of GI adverse events due to long-term NSAIDs use in Malaysian patients with chronic rheumatic diseases is modest.
| Item Type: | Article |
|---|---|
| Funders: | Investigator Initiated Research Grant from Pfizer Pharmaceuticals, no. WI194385 |
| Uncontrolled Keywords: | economic implication; non-steroidal anti-inflammatory drugs; upper gastrointestinal adverse event |
| Subjects: | R Medicine |
| Divisions: | Faculty of Medicine |
| Depositing User: | Ms. Juhaida Abd Rahim |
| Date Deposited: | 19 Apr 2019 01:26 |
| Last Modified: | 19 Apr 2019 01:26 |
| URI: | http://eprints.um.edu.my/id/eprint/21018 |
Actions (login required)
 |
View Item |
